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Hepatocellular carcinoma (HCC) is the predominant primary 
liver cancer in many countries and is the third most com-
mon cause of cancer-related death in the Asia-Pacific region. 
The incidence of HCC is higher in men and in those over 
40 years old. In the Asia-Pacific region, chronic hepatitis B 
virus and hepatitis C virus infections are the main etiological 
agents; in particular, chronic hepatitis B infection (CHB) is 
still the major cause in all Asia-Pacific countries except for 
Japan. Over the past two decades, the incidence of HCC has 
remained stable in countries in the region except for Singa-
pore and Hong Kong, where the incidence for both sexes is 
currently decreasing. Chronic hepatitis C infection (CHC) is 
an important cause of HCC in Japan, representing 70% of 
HCCs. Over the past several decades, the prevalence of CHC 
has been increasing in many Asia-Pacific countries, including 
Australia, New Zealand, and India. Despite advancements in 
treatment, HCC is still an important health problem because 
of the associated substantial mortality. An effective surveil-
lance program could offer early diagnosis and hence better 
treatment options. Antiviral treatment for both CHB and 
CHC is effective in reducing the incidence of HCC. (Gut Liver 
2016;10:332-339)
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cidence; Mortality; Prevalence
EPIDEMIOLOGY
Hepatocellular carcinoma (HCC) is a primary malignant neo-
plasm derived from hepatocytes, accounting for about 80% of 
all liver cancers. Other types of liver cancers, including intrahe-
patic cholangiocarcinoma, hepatoblastoma and angiosarcoma, 
are relatively rare compared to HCC. Therefore, the morbidity of 
liver cancer can be regarded to be a broadly accurate reflection 
of HCC incidence.1,2 
HCC is the sixth most common cancer worldwide, being the 
fifth in men and the eighth in women. It accounts for approxi-
mately 5.7% of all new cancer cases. Annually, around 1% of 
all deaths in the world were related to HCC. Therefore HCC is 
one of the cancers with the highest mortality rates worldwide.3 
Liver cancer is a major health problem in developing countries. 
The highest age adjusted incidence rates (>20 per 100,000) are 
recorded in East Asia (North and South Korea, China, and Viet-
nam), and sub-Saharan Africa, which accounts for 82% of liver 
cancer cases worldwide. In particular, 55% of all HCC cases 
worldwide are reported from China.4 A medium-high incidence 
rate is found in Southern Europe, whereas low-incidence areas 
(<5 per 100,000) are found in South and Central America, and 
the rest of Europe.5 
The global age distribution of HCC varies by region, gender, 
and etiology.6 Globally, the rate of men suffering from HCC 
is higher than women, with the male to female ratio ranging 
between 2:1 and 4:1, with the difference being much greater 
in high-risk areas. In the Asia-Pacific region (especially North 
and South Korea, Indonesia, and Vietnam), the rate of HCC in 
men is greater than 4 folds than that of women. In most high-
risk Asia-Pacific populations (e.g., Hong Kong), the highest age-
specific rates are people aged beyond 75, which is similar to 
that in the most low-risk Western countries. On the other hand, 
the age-specific rates of men in high-risk African populations 
(e.g., Gambia and Mali) tend to peak in the 60 to 65 age group, 
while that of women peak between 65 and 70 years old. These 
variations of age-specific patterns are likely related to the differ-
ences in the dominant hepatitis virus in the population, the age 
at viral infection as well as the existence of other risk factors.1,7
RISK FACTORS
Based on available epidemiological data, HCC is a complex 
disease entity with multiple possible etiologies, and associated 
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with many risk factors and cofactors.8,9 Approximately 70% 
to 90% of patients with HCC have an available case history of 
chronic liver disease and liver cirrhosis, with major risk fac-
tors including chronic infection with hepatitis B virus (HBV), 
hepatitis C virus (HCV), alcoholic liver disease, and nonalcoholic 
steatohepatitis (NASH).10,11 Additional risk factors for developing 
HCC include intake of aflatoxin-contaminated food, diabetes, 
obesity, certain hereditary conditions such as hemochromatosis, 
and various metabolic disorders.8,10,12 
1. Hepatitis B virus
Chronic HBV infection (CHB) has a well-known association 
with HCC.13 It is estimated that HBV is responsible for 50% to 
80% of HCC cases worldwide. Moreover, it is the cause of 75% 
to 90% of HCC in HBV endemic or hyperendemic regions.14 
Globally, 270 million people are infected with CHB, which is 
almost 5% of the world’s populations; the majority of whom 
are found in the HCC high-risk regions of Asia-Pacific and sub-
Saharan Africa.15 Currently, 75% of CHB carriers are found in 
Asia. In this region, CHB accounts for 80% of all newly diag-
nosed HCC. Certain Asia-Pacific countries have a lower HCC 
incidence, including Singapore, Japan, India, Pakistan, and Sri 
Lanka.16
1) HBV DNA level 
According to a population-based study on the relationship 
between CHB and HCC, the risk of HCC in patients with high 
HBV DNA load (>2,000 IU/mL equivalent to 10,000 copies/mL) 
is much greater than those who have low levels.17,18 The as-
sociation of high HBV DNA levels with HCC is independent of 
hepatitis B e antigen (HBeAg)-positivity, serum alanine amino-
transferase levels, and liver cirrhosis.19-22 In the cohort of 3,653 
patients who were hepatitis B surface antigen (HBsAg) positive 
and anti-HCV negative recruited between 1991 and 1992 in Tai-
wan, the incidence of HCC increased in proportion to the serum 
HBV DNA levels, ranging from 108 per 100,000 patient-years 
for HBV DNA levels of <300 copies/mL to 1,152 per 100,000 
patient-years for HBV DNA levels >200,000 IU/mL (1,000,000 
copies/mL). Another study demonstrated patients with moder-
ate HBV DNA levels (60 to 2,000 IU/mL), when compared to 
individuals without HBV infection, also had a higher risk of 
HCC and liver-related death. Among all other risk factors, serum 
HBV DNA is the most important viral predictor of HBV-related 
HCC.17,18
2) Other HBV viral factors
HBV genotype C is closely associated with HCC in patients 
aged >50 years.23 When compared to genotype B, HBV geno-
type C has been shown to be an independent risk factor for HCC 
development.24 More recent data also indicate high serum HB-
sAg levels to increase the risk of HCC development, especially 
among patients with intermediate HBV DNA levels.25,26 Combi-
nation of HBV DNA and HBsAg levels could further improve 
the risk stratification of HCC. 
2. Hepatitis C virus
The contribution of HCV infection to HCC varies worldwide. 
HCV is a major cause of HCC in Western countries and Africa; 
it also accounts for 80% to 90% of HCC cases in Japan.27,28 
HCV infection causes chronic inflammation, proliferation, and 
cirrhosis of the liver.29 The liver cirrhosis caused by HCV can 
increase the risk for liver cancer, which was 17-fold higher risk 
in developing HCC than only than just chronic hepatitis C infec-
tion (CHC), although this risk varies and depends on the degree 
of HCV-related liver fibrosis.30
Coinfections with HBV and HCV may produce a cumulative 
effect on the development of HCC which varies from additive to 
synergistic. Thus, globally, the burden of liver cancer attribut-
able to viral infections is likely to be close to 90%.
3. Cirrhosis
Cirrhosis is present in about 80% to 90% of HCC and has a 
prominent role in the development of HCC.31 Unlike in Western 
countries, where a considerable proportion of cirrhosis are as-
sociated with alcoholic liver disease, HBV and HCV remain the 
most the important cause of cirrhosis in the Asia-Pacific region. 
However, only around 80% of HBV-related HCC have underly-
ing cirrhosis of the liver, the remaining 20% develop HCC be-
cause of the direct oncogenic effect of HBV.
4. Aflatoxin-contaminated food
Aflatoxin B1 is a kind of hepatocarcinogenic mycotoxins 
which is produced by certain aspergillus species. They can con-
taminate a large number of traditional foods, including grains, 
corn, cassava, peanuts, and fermented soy beans, which are 
produced in the humid areas of Southeast Asia. Aflatoxin B1 
can induce DNA mutations, particularly the tumor suppressor 
p53 gene, resulting in downregulation of p53 in 30% to 60% of 
all HCCs in these areas.32 In addition, it has been found that in-
dividuals with HBV infection and significant intake of aflatoxin 
have an even higher risk of liver cancer compared with HBV in-
fection alone, suggesting a synergistic effect between HBV and 
aflatoxin.33
5. Alcohol
Heavy alcohol intake, defined as ingestion of >50 to 70 g/
day for prolonged periods, is a well-established HCC risk factor. 
Although it is reported that alcohol does not have a carcino-
genic effect in itself, prolonged alcohol intake can increase the 
risk of cirrhosis, a major risk factor for HCC. On the other hand, 
some evidence show that heavy alcohol ingestion can increase 
the risk of HCC induced by HCV or HBV infection by actively 
promoting the formation of cirrhosis.34 One study demonstrated 
that among heavy alcohol drinkers, HCC risk increased in a lin-
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ear fashion at intake >60 g alcohol on a daily basis and the risk 
rate was doubled with concomitant HCV infection.30 
6. Diabetes
Type 2 diabetes mellitus is considered to be an important risk 
factor for both chronic liver disease and HCC possibly by facili-
tating the development of nonalcoholic fatty liver disease and 
NASH. Data emerging from epidemiologic studies have shown a 
longer duration of diabetes to be associated with increased risk 
of HCC.34,35 A population-based study has reported that diabetes 
(type 2) is an independent risk factor for HCC, increasing the 
risk by 2- to 3-fold.36 Similar data is also found in Asia, with 
a case-control study showing diabetes to increase the risk of 
HCC.36,37 
ASIA-PACIFIC COUNTRIES 
HCC in Asia-Pacific countries has a wide geographic vari-
ability. Most of the countries have epidemiological data of HCC 
in place. These include Australia, China, Hong Kong (Special 
Administrative Region, China), Singapore, Japan, India, New 
Zealand, and Taiwan (Fig. 1).
1. Australia 
Over the recent decades, the incidence and mortality of HCC 
in Australia have been gradually increasing. The cause of rising 
HCC incidence is partly attributed to the mass migration from 
the Asia-Pacific region,38,39 with the majority of immigrants 
coming from high-risk HBV endemic countries. Other known 
risk factors for the increasing incidence of HCC include HBV/
HCV coinfection, cirrhosis due to other various causes. 
According to an Australian study of HCC incidence as strati-
fied by different chronic liver diseases, the HCC incidence rate 
of patients with HBV mono-infection was markedly higher 
than that of those with HCV mono-infection (9.5 vs 6.9 cases 
per 10,000 person years, p<0.001).40 It is estimated that 50% to 
65% of CHB cases in Australia are among people born in Asian 
countries.41 A recent population-based linkage study showed 
that Asian-born residents with CHB were 30 times more likely 
to develop HCC compared with Australian born residents.42 The 
incidence of HCC with chronic viral hepatitis is associated with 
increasing age, male gender and other comorbidities. The high-
est risk of age-specific rates in developing HCC occurs among 
people aged 75 and older, which is over 14 times the risk of 
those aged under 45. The risk in male patients is 3-fold higher 
than that in women. The same phenomena are observed in the 
HCV-related HCC.40 
2. China
Liver cancer is the second most common cancer in China af-
ter lung cancer. Overall, the estimated incidence rate of HCC is 
40.0 in males and 15.3 in females per 100,000 world standard 
population. Concerning the annual mortality rate for the five 
common malignant neoplasms in China, liver cancer ranked as 
the second cause of cancer mortality in male after lung can-
cer; while it ranked the third in female after lung and gastric 
cancer. The mortality rate of liver cancer is higher in males 
(37.4/100,000) than in females (14.3/100,000).43 
In China, some identified risk factors such as HBV, HCV, afla-
toxin, alcohol consumption, and tobacco smoking contribute to 
the incidence and mortality of HCC. Particularly, HBV infection 
contributes to large number of liver cancer deaths and cases 
(63.9%), including 65.9% among men and 58.4% among wom-
en. For HCV, its rate in liver cancer deaths and cases is lower 
than that of HBV (27.7% overall; 27.3% in men and 28.6% in 
women), but is still higher than that of aflatoxin exposure (25% 
of population), alcohol drinking (15.7%), and tobacco smoking 
(13.9%).44
Despite the high incidence of liver cancer throughout China, 
trends of decrease have been observed in some regions. Accord-
ing to the International Agency for Research on Cancer and 
Cancer Incidence in Five Continents, the age-adjusted incidence 
rate of HCC has been in decline in Shanghai city since 1970s45 
and in Tianjin city since 1980s.46,47 In Qidong, a district near 
Shanghai, the incidence rate has not changed since 1978, ex-
cept for subjects between age 15 to 34 years, in whom there is a 
decreasing tendency from 1988 to 2002.48
3. Hong Kong 
According to the report from the Hong Kong Cancer 
Registry 2012 (http://www3.ha.org.hk/cancereg/Statistics.
html#cancerfacts),49 liver cancer ranks as the fourth most com-
mon cancer and the third most common cause of cancer death. 
The incidence and mortality of liver cancer is higher in man 
(fourth and third respectively among all cancers) than that in 
Fig. 1. The proportions of hepatitis B virus (HBV)- and hepatitis C 
virus (HCV)-related hepatocellular carcinoma in different Asia-Pacific 
regions. The data source for each country was as follows: China,44 
Hong Kong,50 India,52 Japan,54 Singapore,58 Korea,55 and Taiwan.60
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woman (10th and fourth respectively among all cancers). 
In Hong Kong, the incidence of HCC increases with age. As 
depicted in Fig. 2, the highest age-specific rate occurs among 
people aged 75 and older, accounting for 152.4 per 100,000 
persons. However, over the past 25 years, the incidence of HCC 
at different age groups (especially age >40 years) has an appar-
ently downward trend, which may be partly explained by the 
declining rate of HBV infection due to the institution of univer-
sal HBV vaccination since 1988. As depicted in Table 1, during 
the period of 1992 to 2006, CHB is the major cause of HCC in 
Hong Kong, accounting for 80% cases in 1992 and 78% cases 
in 2006. From 1992 to 2006, the proportion of HCV-related HCC 
has increased from 3% to 6.3%.50
4. India 
Based on Cancer Registries in five Indian urban populations 
(Mumbai, Bangalore, Chennai, Delhi, and Bhopal), liver cancer 
ranks as the fifth most frequent cancer for both genders. Over 
the period of the last two decades, the observed and estimated 
age adjusted incidence rates according to different registries 
have increased, especially in the Mumbai, Chennai, and Ban-
galore registries. The incidence of HCC is higher in men when 
compared to women, as illustrated by a study cohort of 213 
patients with HCC in 1999–2005 in which 83.1% were male pa-
tients.51
In India, HBV infection, HCV infection and alcohol consump-
tion are the main causes of HCC. Based on the above mentioned 
study cohort, in the 213 HCC patients, HBV positive mark-
ers accounted for 150 (70.42%; odds ratio [OR], 48.0%); HCV 
positive markers accounted for 26 (12.21%; OR, 5.45%); HBV/
HCV coinfection was responsible for 10 (4.69%). Heavy alcohol 
intake was found in 34 (15.96%; OR, 2.83%). A synergistic ef-
fect between HCV and alcohol was also found (synergy index, 
1.257). There was no evidence of interaction between HBV and 
alcohol.52
5. Japan 
In Japan, HCC ranks as the fourth most common cancer for 
both genders. Among all cancers in Japan, HCC is the third in 
men, whereas it is the fifth in women. According to a study 
based on the Osaka Cancer Registry from 1981 to 2003, the 
incidence rate of HCC was higher in men than in women. Over 
the past 22 years, the age-standardized incidence rate of HCC in 
men had climbed from 29.2 per 100,000 cases in 1981 to 41.9 
per 100,000 cases in 1987, and then fluctuated within a similar 
range for 8 years until 1995. After that, there was a gradual de-
clining trend. On the other hand, the age-standardized incidence 
rate of HCC in women remained static.53
Although Japan is one of Asia-Pacific countries with a high 
HCC incidence rate, the cause of HCC in Japan differs greatly 
from other countries in the region. Chronic HCV infection is 
more common than HBV in Japan (Fig. 3), and hence HCV ac-
counts for 79% of HCC. HBV infection, on the other hand, only 
accounts for 11% of HCC. A survey from the Liver Cancer Study 
Group of Japan in the period of 1990 to 2003 revealed that 
anti-HCV-positive cases of HCC accounted for more than 70% 
of cases diagnosed, whilst HBsAg-positive cases of HCC consti-
Table 1. Etiologies and Demographics of HCC in Hong Kong
Lai et al.  
(1981)64
Lai et al.  
(1987)65
Shiu et al.  
(1990)66
Leung et al.  
(1992)67
Yuen et al.  
(2000)50
Cheung et al.  
(2006)68
No. 211 186 340 424 306 223
HBV, % -  75 -  80  79  78
HCV, % - - -  3 4.9  6.3
HBV+HCV, % - - -  3 1.3  0.4
Alcohol, % - - - - 5.6  5.8
Median age, yr - - - - 61  63
Male:female - 5:1 - - 4:1  4:1
Median survival 3.5 wk 8–10 wk 8 wk - 11 mo 11 mo
HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus. 
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Fig. 2. The incidence rates of hepatocellular carcinoma (HCC) in both 
sexes among different age groups in Hong Kong (data from the report 
of the Hong Kong Cancer Registry, 2012).49 Age-specific incidence 
rates for liver cancer in 2012.
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tuted less than 20% of cases. Some cross-sectional studies de-
rived from Shinshu University Hospital in Japan further showed 
that HCV-related HCC constitute the vast majority of cases since 
1990s. In 2002 to 2007, HCV-related HCC accounted for 72%; 
HBV-related HCC accounted for 18%; and non-HBV non-HCV 
HCC (NBNC-HCC) accounted for 10%. Moreover, the nationwide 
health screening for the seroprevalence of HBsAg and anti-HCV 
in Japanese aged over 40 years found HCV infection to be sig-
nificantly associated with HCC mortality, this association was, 
however, not found in HBV infection.54 
6. Korea
HCC is substantially prevalent in Korea, ranking as the third 
common cancer and the third leading cause of cancer mortality. 
The age-standardized incidence rate is 46.5 per 100,000 popula-
tions; 45 per 100,000 in men and 12 per 100,000 in women. 
The incidence increases when age is over 40 years old, reaching 
a peak at the age of 55 years. In Korea, HBV infection accounts 
for 74.2% of HCC; HCV infection accounts for 8.6% of HCC; 
and heavy alcoholism accounts for 6.9%.55
7. New Zealand
New Zealand is known for its ethnic diversification. At pres-
ent, Pacific peoples constitute 6.9% of New Zealand popula-
tion, with 33% of the Pacific population aged under 15 years.56 
Therefore, the percentage of Pacific peoples in New Zealand 
is expected to increase in the future. However, there has been 
nearly no data on specific cancer incidence rates among Pacific 
peoples in New Zealand. HCC, as one of the common cancers 
in Asia-Pacific region, is also prevalent in Pacific peoples. 
New Zealand census-cancer data from 1981 to 2004 indicates 
that the age-standardized incidence rate of HCC was 30.3 per 
100,000 in men and 9.8 per 100,000 in women, compared with 
4.1 per 100,000 and 2.1 per 100,000 for their European counter-
parts. This suggests that the rate of HCC in Pacific is beyond 7 
and 4 times higher than European for men and women, respec-
tively.57 
8. Singapore
Based on the Singapore Cancer Registry 2002 to 2005, HCC 
ranks the fourth most common cancer in men. A survey dem-
onstrated that the age standardized incidence of HCC in men 
declined from 17.1 per 100,000 in 1968–1972 to 6 per 100,000 
in 1988–1992, then increased slowly to 7.1 per 100,000 in 
1998–2002. Over this whole time period, the total HCC inci-
dence declined by 58%. At the same time, the rate in women 
had a similar but slower declining trend, from 2.8 in 1968–1972 
to 1.5 per 100,000 persons in 1998–2002.58 According to the 
records from Ministry of Health in Singapore, the overall preva-
lence of CHB infection in Singapore has fallen from 9%–10% 
in 1980–1981 to 4% in 1999. In a cohort study of 288 patients 
with HCC diagnosed during 2002 to 2007 in the National Uni-
versity Hospital, 74% of patients were male and 76% were of 
Chinese ethnicity; 35% had CHB; 13% had CHC; and 31.4% had 
HCC of other causes.
9. Taiwan
A survey from the Taiwan Cancer Registration System docu-
mented the incidence rate of HCC had increased gradually in 
1994 to 2007. The rate in men was greatly higher than that in 
women. In 2002, the age-standardized incidence rates were 53 
per 100,000 for men and 21 per 100,000 for women. HBV in-
fection is thought to be the most important cause of HCC, but 
this phenomenon is changing. In 1981 to 1985, HBV-related 
HCC accounted for 88% of cases, whereas in 1995 to 2000, the 
proportion of HBV-related HCC had decreased to 59%, whereas 
the proportion of HCV-related HCC had increased to 31%, with 
HBV-HCV coinfection accounting for 4% of HCC cases. A study 
of 18,423 patients with HCC from 1981 to 2001, 67% of male 
patients with HCC suffered with CHB, but 55% of female pa-
tients had HCV-related HCC.59 The average age of patients with 
HBV-related HCC was 53±14 years, while for those with HCV-
related HCC, it was 65±9.1 years (p<0.001). For HBV-related 
HCC, the ratio between men and women was 6.4; whereas for 
HCV-related HCC, it was 1.7. During the period between 1981 
and 2001, the percentage of HBV-related HCC in men declined 
from 82% to 66%, and that of women was from 67% to 41%. 
Overall, the declining incidence of HBV-related HCC was not 
only due to the effects of universal HBV vaccination,60 but also 
due to the increase in HCV-related HCC. 
CONCLUSIONS
In Asia-Pacific region, HCC remains as a highly prevalent 
disease with high mortality, although progress has been made 
through the introduction of HBV vaccination programs. During 
the period between 2000 and 2005, the incidence and mortality 
Fig. 3. The relative incidences of hepatitis B virus (HBV) and hepatitis 
C virus (HCV) infection in different Asia-Pacific regions.62,63
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of liver cancer in men is higher than that in women (summarized 
in Fig. 4).61 For both genders, the incidence of HCC increases 
with age among ≥40 years.
The most prevalent etiological agents of HCC in Asia-Pacific 
region are CHB infection, followed by CHC. The relative in-
cidence of HBV and HCV in each Asian-Pacific country is 
depicted in Fig. 3.62,63 The major cause of HCC in Asia-Pacific, 
with the exception of Japan, remains to be HBV. Over the recent 
20 years, the incidence of HCC remains static in some countries 
of the region except for Singapore and Hong Kong where inci-
dence for both genders have a decreasing trend, which could be 
partly explained by the decline of HBV prevalence. 
China has reported an increasing incidence of HCC for both 
genders which may be due to increasing awareness of record 
and better screening services. Australia, an immigrant country, 
is thought traditionally to be very low HCC incidence regions. 
However, over the last 25 years, there has been an obvious 
increase (2- to 3-fold) in HCC incidence, which probably due 
to immigrants from Asia-Pacific and other regions with high 
prevalence rates of CHB infection. And in Taiwan, there is the 
increasing incidence of HCC, which is partly due to an increase 
in HCV-related HCC. Japan, as one of high-risk HCC incidence 
area, has higher HCV infection compared with HBV infection. 
The investigation from the Vital Statistics of Japan in 2007 
showed that the incidence of HCC was not associated with the 
infection of HBV, but correlated significantly with the preva-
lence of HCV. A possible consideration for this discrepancy is 
the HBV genotype Bj, which shows good clinical progress.54 
Therefore, HCV infection plays a more important role in certain 
countries, e.g., Japan and Taiwan.
Efforts against HCC should be directed toward an effective 
surveillance program, leading to early diagnosis and effective 
treatment, and preventive measures for chronic virus hepatitis.
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